<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">636218</article-id><article-id pub-id-type="doi">10.17816/KMJ636218</article-id><article-id pub-id-type="edn">HKVEUA</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Theoretical and clinical medicine</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Теоретическая и клиническая медицина</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Development of prognostic models for bone mineral density disorders in patients with hodgkin lymphoma: a cross-sectional study</article-title><trans-title-group xml:lang="ru"><trans-title>Разработка прогностических моделей проблем костной ткани у пациентов с лимфомой Ходжкина: одномоментное исследование</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>霍奇金淋巴瘤患者骨组织病变预测模型的构建：一项横断面研究</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-5049-1626</contrib-id><contrib-id contrib-id-type="spin">3800-4721</contrib-id><name-alternatives><name xml:lang="en"><surname>Badykova</surname><given-names>Kseniya M.</given-names></name><name xml:lang="ru"><surname>Бадыкова</surname><given-names>Ксения Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>graduate student, Depart. of Therapy</p></bio><bio xml:lang="ru"><p>аспирант, каф. терапии</p></bio><email>badykova.gem@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4092-6305</contrib-id><contrib-id contrib-id-type="spin">2653-9401</contrib-id><name-alternatives><name xml:lang="en"><surname>Kitaeva</surname><given-names>Julija S.</given-names></name><name xml:lang="ru"><surname>Китаева</surname><given-names>Юлия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Lecturer, Depart. of Propaedeutics of Internal Diseases</p></bio><bio xml:lang="ru"><p>канд. мед. наук, ассистент, каф. пропедевтики внутренних болезней</p></bio><email>JKhema@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9523-5966</contrib-id><contrib-id contrib-id-type="spin">5628-1986</contrib-id><name-alternatives><name xml:lang="en"><surname>Praskurnichij</surname><given-names>Evgenij A.</given-names></name><name xml:lang="ru"><surname>Праскурничий</surname><given-names>Евгений Аркадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Head, Depart. of Therapy</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующий, каф. терапии</p></bio><email>praskurnichey@mail.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1631-486X</contrib-id><contrib-id contrib-id-type="spin">1178-7293</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuznetsova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Кузнецова</surname><given-names>Елена Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor, Depart. of Propaedeutics of Internal Diseases</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент, каф. пропедевтики внутренних болезней</p></bio><email>aliska@k66.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7653-6620</contrib-id><contrib-id contrib-id-type="spin">1521-9584</contrib-id><name-alternatives><name xml:lang="en"><surname>Nagieva</surname><given-names>Amaliya R.</given-names></name><name xml:lang="ru"><surname>Нагиева</surname><given-names>Амалия Романовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>graduate student, Depart. of Therapy</p></bio><bio xml:lang="ru"><p>аспирант, каф. терапии</p></bio><email>nagieva281@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Scientific Center of the Russian Federation—Federal Medical Biophysical Center named after A.I. Burnazyan</institution></aff><aff><institution xml:lang="ru">Государственный научный центр Российской Федерации — Федеральный медицинский биофизический центр им. А.И. Бурназяна</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ural State Medical University</institution></aff><aff><institution xml:lang="ru">Уральский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Central State Medical Academy</institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">The Russian National Research Medical University named after N.I. Pirogov</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-04-07" publication-format="electronic"><day>07</day><month>04</month><year>2026</year></pub-date><volume>107</volume><issue>2</issue><issue-title xml:lang="en">Kazan medical journal</issue-title><issue-title xml:lang="ru">Казанский медицинский журнал</issue-title><fpage>189</fpage><lpage>199</lpage><history><date date-type="received" iso-8601-date="2024-09-18"><day>18</day><month>09</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-04-23"><day>23</day><month>04</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2026,</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-04-07"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/636218">https://kazanmedjournal.ru/kazanmedj/article/view/636218</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Assessment of the need for prevention of decreased bone mineral density in young individuals with Hodgkin lymphoma after pathogenetic therapy is relevant, as they face an increased risk of such long-term complications as frequent fractures.</p> <p><bold>AIM:</bold> This study aimed to develop prognostic models for assessing the need for prevention of decreased bone mineral density in young patients with Hodgkin lymphoma after standard pathogenetic therapy.</p> <p><bold>METHODS: </bold>This single-center cross-sectional study included 93 participants: 63 patients with an established diagnosis of Hodgkin lymphoma and 30 healthy volunteers aged 17–45 years. The study was conducted at the Department of Oncohematology, Chemotherapy, and Bone Marrow Transplantation of the Sverdlovsk Regional Clinical Hospital No. 1 (Yekaterinburg). Data were collected from 2018 to 2023. Each participant completed a questionnaire recommended by the Institute of Rheumatology to assess fracture risk factors. Dual-energy x-ray absorptiometry was performed in all patients to evaluate bone tissue status. The models were constructed using multivariate logistic regression. Model performance was assessed by the area under the ROC curve (AUC), as well as by accuracy, sensitivity, and specificity.</p> <p><bold>RESULTS: </bold>Two models were developed to assess the risk of osteoporosis and the need for early initiation of preventive measures for decreased bone mineral density in patients with Hodgkin lymphoma. The first model, based on questionnaire results, had an AUC of 0.727, accuracy of 71.4%, sensitivity of 75%, and specificity of 66.7%. The second model, which included densitometric parameters, demonstrated higher performance: ROC-AUC of 0.95, accuracy of 88.6%, sensitivity of 95%, and specificity of 80%.</p> <p><bold>CONCLUSION:</bold> Both models may be used as screening tools; however, the model based on densitometric parameters has higher diagnostic performance. The use of the model without densitometric data appears acceptable for preliminary identification of indications for preventive measures in patients with Hodgkin lymphoma.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>. Оценка необходимости профилактики снижения минеральной плотности костной ткани у лиц молодого возраста с лимфомой Ходжкина после патогенетической терапии актуальна в связи с риском развития отдалённых осложнений в виде частых переломов.</p> <p><bold>Цель исследования</bold>. Разработать прогностические модели для оценки необходимости профилактики снижения минеральной плотности костной ткани у пациентов молодого возраста с лимфомой Ходжкина после стандартной патогенетической терапии.</p> <p><bold>Методы</bold>. В одноцентровое одномоментное исследование включены 93 пациента: 63 — с установленным диагнозом лимфомы Ходжкина и 30 здоровых добровольцев в возрасте 17–45 лет. Исследование проведено на базе отделения онкогематологии, химиотерапии и трансплантации костного мозга ГАУЗ СО «Свердловская областная клиническая больница № 1» (Екатеринбург). Набор материала осуществляли в период с 2018 по 2023 год. Каждый участник заполнил анкету, рекомендованную институтом ревматологии для изучения факторов риска переломов. Всем пациентам выполнена двухэнергетическая рентгеновская абсорбциометрия для оценки состояния костной ткани. Модели построены с использованием многофакторной логистической регрессии. Качество моделей оценивали по площади под ROC-кривой (AUC), а также по показателям точности, чувствительности и специфичности.</p> <p><bold>Результаты</bold>. Построены две модели оценки риска развития остеопороза и необходимости раннего начала профилактических мероприятий снижения минеральной плотности костной ткани у пациентов с лимфомой Ходжкина. Первая модель, основанная на результатах анкетирования, имела AUC — 0,727, точность — 71,4%, чувствительность — 75%, специфичность — 66,7%. Вторая модель, включающая денситометрические показатели, продемонстрировала более высокие параметры качества: ROC-AUC — 95%, точность — 88,6%, чувствительность — 95%, специфичность — 80%.</p> <p><bold>Заключение</bold>.<bold> </bold>Обе модели могут использоваться в качестве скрининговых инструментов, однако модель, основанная на<bold> </bold>денситометрических показателях, обладает более высокой диагностической эффективностью. Использование модели без учёта денситометрических данных представляется приемлемым для предварительного определения показаний к проведению профилактических мероприятий у пациентов с лимфомой Ходжкина.</p></trans-abstract><trans-abstract xml:lang="zh"><p><bold>论证</bold>：霍奇金淋巴瘤年轻患者在接受规范治疗后，骨密度降低的预防评估具有重要的临床意义。该人群在治疗后发生骨量流失，进而导致脆性骨折等远期并发症的风险较高，因此对其开展预防性干预评估显得尤为紧迫。</p> <p><bold>目的</bold>：本研究旨在构建一套预测模型，用于评估青年霍奇金淋巴瘤患者在完成规范化病理机制导向治疗后，其骨密度降低的风险，并据此判定临床预防性干预的必要性。</p> <p><bold>方法</bold>：本研究为单中心横断面研究，共纳入 93 例研究对象，其中霍奇金淋巴瘤（HL）组 63 例，健康对照组 30 例，年龄范围为 17–45 岁。研究地点为斯维尔德洛夫斯克州第一临床医院（Sverdlovsk Regional Clinical Hospital No. 1）肿瘤血液、化疗及造血干细胞移植科。病例收集时段为 2018 年至 2023 年。所有参与者均填写了经风湿病研究所推荐的骨折风险评估问卷。对所有患者均行双能 X 线吸收法检测，以评估骨密度状况。采用多因素逻辑回归分析构建预测模型。模型效能评价指标包括受试者工作特征（ROC）曲线下面积（AUC）、精确度、灵敏度及特异度。</p> <p><bold>结果</bold>：本研究构建了两项预测模型，分别用于评估霍奇金淋巴瘤患者骨质疏松的发生风险，以及早期开展预防骨密度流失干预措施的必要性。基于问卷调查因素构建的第一项模型，其 AUC 为 0.727，准确度为 71.4%，灵敏度为 75%，特异度为 66.7%。整合了骨密度测量指标的第二项模型展现出更高的预测效能：ROC-AUC 为 95%，准确度为 88.6%，灵敏度为 95%，特异度为 80%。</p> <p><bold>结论</bold>：上述两种模型均可作为筛查工具使用，但基于骨密度测量指标构建的模型展现出更高的诊断效能。对于霍奇金淋巴瘤患者，在缺乏骨密度数据的情况下，采用第一种预测模型进行预防性干预指征的初步筛查是可行的。</p></trans-abstract><kwd-group xml:lang="en"><kwd>Hodgkin lymphoma</kwd><kwd>osteoporosis</kwd><kwd>bone density</kwd><kwd>machine learning</kwd><kwd>multivariate logistic regression</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфома Ходжкина</kwd><kwd>остеопороз</kwd><kwd>минеральная плотность костной ткани</kwd><kwd>машинное обучение</kwd><kwd>многофакторная логистическая регрессия</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>霍奇金淋巴瘤</kwd><kwd>骨质疏松</kwd><kwd>骨密度</kwd><kwd>机器学习</kwd><kwd>多因素逻辑回归</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Galimzyanov HM, Trizno NN, Lopukhin YuM, et al. The predictive-preventive and personalied medicine as a new branch of health protection and its perspectives. Astrakhan medical journal. 2013;(1):64–68. EDN: QCYCQJ</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Tarasova S. Prognostication in the clinical medicine. Innovatsii v nauke. 2014;(30-2):57–61. EDN: RWVLRV</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Luchinin AS. Prognostic Models in Medicine. Clinical oncohematology. 2023;16(1):27–36. doi: 10.21320/2500-2139-2023-16-1-27-36 EDN: UZEQZU</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Karyakina OE, Dobrodeeva LK, Martynova NA, Karyakina TI. Use of mathematical models in clinical practice. Human Ecology. 2012;(7):55–64. EDN: OZLWTD</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dimitriyev DA, Dimitriyev AD, Vorontsova GM. Use of the bayes classification for assessing an individual risk. Hygiene and sanitation, Russian journal. 2003;(4):64–66. EDN: OIWRJJ</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kitaeva YS, Praskurnichy EA. Algorithm for assessment of risk factors for bone mineral density disorders in pathogenetic therapy for Hodgkin's lymphoma. Siberian Medical Review. 2023;(1):31–36. doi: 10.20333/25000136-2023-1-31-36 EDN: VDLHEQ</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Luchinin AS. Artificial Intelligence in Hematology. Clinical oncohematology. 2022;15(1):16–27. doi: 10.21320/2500-2139-2022-15-1-16-27 EDN: ISVFJA</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bunimovich-Mendrazitsky S, Byrne H, Stone L. Mathematical model of pulsed immunotherapy for superficial bladder cancer. Bulletin of Mathematical Biology. 2008;70(7):2055–2076. doi: 10.1007/s11538-008-9344-z EDN: LSCFPX</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(11):1478–1488. doi: 10.1002/ajh.26717</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Seam P, Janik JE, Longo DL, Devita VT. The Role of Chemotherapy in Hodgkin's Lymphoma. Cancer. 2009;15(2):150–154. doi: 10.1097/PPO.0b013e3181a27018</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rizzoli R, Body J-J, Brandi M-L, et al. Cancer-associated bone disease. Osteoporosis International. 2013;24(12):2929–2953. doi: 10.1007/s00198-013-2530-3 EDN: SOHFFF</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kitaeva YS, Praskurnichiy EA. Predictors of Bone Mineral Density Reduction in Patients with Hodgkin's Lymphoma Associated with Pathogenetic Therapy. The Russian Archives of Internal Medicine. 2023;13(1):36–45. doi: 10.20514/2226-6704-2023-13-1-36-45 EDN: LHFKGU</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Voitko MS, Pospelova TI, Klimontov VV, Mezit EV. Factors influencing bone tissue remodeling in patients with Hodgkin's lymphoma (literature review). Siberian Scientific Medical Journal. 2018;38(4):65–72. doi: 10.15372/SSMJ20180408 EDN: XWBYOD</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ofshenko N, Bercovich E, Mashiach T, Weiler-Sagie M. Reduction of the vertebral bone mineral density in patients with Hodgkin lymphoma correlates with their age and the treatment regimen they received. Cancers. 2022;14(3):495. doi: 10.3390/cancers14030495 EDN: KECSAX</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Belaya ZhE, Belova KYu, Biryukova EV, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4–47. doi: 10.14341/osteo12930 EDN: TUONYE</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kiku PF, Zhigaev DS, Shiter NS, et al. The concept of risk factors for the health of the population. Bulletin of physiology and pathology of respiration. 2016;(62):101–109. doi: 10.12737/23260 EDN: XYEAZX</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Nikitinskaya OA, Toroptsova NV. Ocenka riska perelomov s ispol'zovaniem modeli FRAX® (retrospektivnoe desyatiletnee issledovanie). Almanac of Clinical Medicine. 2014;(32):50–55. EDN: SXYJPF</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Demina EA, Tumyan GS, Moiseeva TN, et al. Hodgkin Lymphoma. Clinical recommendations. Journal of Modern Oncology. 2020;22(2):6–33. doi: 10.26442/18151434.2020.2.200132 EDN: MWPSMO</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Skripnikova IA, Shcheplyagina LA, Novikov VE, et al. Vozmozhnosti kostnoy rentgenovskoy densitometrii vklinicheskoy praktike (Metodicheskie rekomendatsii). Osteoporosis and Bone Diseases. 2010;13(2):23–34. (In Russ.) EDN: OGEFDR</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Joseph VR. Optimal Ratio for Data Splitting. Statistical Analysis and Data Mining: The ASA Data Science Journal. 2022;15(4):531–538. doi: 10.1002/sam.11583 EDN: YFUIXT</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kovalev AA, Kuznetsov BK, Yadchenko AA, Ignatenko VA. Assessment of the quality of a binary classifier in research. Health and Ecology Issues. 2020;(4):105–113. doi: 10.51523/2708-6011.2020-17-4-15 EDN: XPCLVS</mixed-citation></ref></ref-list></back></article>
